Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial

被引：0
|
作者：
Yoshiteru Takekita
Yosuke Koshikawa
Chiara Fabbri
Shiho Sakai
Naotaka Sunada
Ai Onohara
Keiichiro Nishida
Masafumi Yoshimura
Masaki Kato
Alessandro Serretti
Toshihiko Kinoshita
机构：
[1] University of Bologna,Department of Biomedical and NeuroMotor Sciences
[2] Kansai Medical University,Department of Neuropsychiatry
来源：
BMC Psychiatry | / 16卷
关键词：
Schizophrenia; Risperidone long-acting injection; Paliperidone palmitate; Cognitive function; Efficacy; Subjective well-being;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] PALIPERIDONE PALMITATE 6-MONTH LONG-ACTING INJECTABLE FOR SCHIZOPHRENIA: A RANDOMISED, DOUBLE-BLIND, MULTICENTER, NON-INFERIORITY PHASE 3 STUDY
    Liu, D.
    Najarian, D.
    Sanga, P.
    Wang, S.
    Lim, P.
    Singh, A.
    Robertson, M. J.
    Cohen, K.
    Schotte, A.
    Milz, R.
    Venkatasubramanian, R.
    T'Jollyn, H.
    Walling, D. P.
    Galderisi, S.
    Gopal, S.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2022, 56 (1_SUPPL): : 220 - 220
  • [42] The influence of switching from oral risperidone to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia
    Suzuki, Hidenobu
    Gen, Keishi
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2012, 2 (01) : 23 - 29
  • [43] Comparison of treatment retention between risperidone long-acting injection, paliperidone palmitate, and aripiprazole once-monthly in elderly patients with schizophrenia
    Suzuki, Hidenobu
    Hibino, Hiroyuki
    PSYCHOGERIATRICS, 2022, 22 (01) : 159 - 160
  • [44] OVERCOMING THE CHALLENGES OF MODELLING SCHIZOPHRENIA: A UK CASE STUDY OF THE COST-EFFECTIVENESS OF OLANZAPINE LONG-ACTING INJECTION VS. RISPERIDONE LONG-ACTING INJECTION
    Carroll, S. M.
    Jemiai, N.
    Moller, J.
    Novick, D.
    VALUE IN HEALTH, 2009, 12 (07) : A350 - A350
  • [45] RISPERIDONE LONG-ACTING INJECTION VS. ORAL RISPERIDONE: ANALYSIS OF RELAPSE AND REHOSPITALIZATION CONTROLLING FOR SWITCHING IN A PRAGMATIC TRIAL
    Schooler, Nina R.
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S333 - S333
  • [46] The effectiveness of the long-acting injections of second generation antipsychotics: A 54-month follow-up study of risperidone long-acting inyection vs paliperidone palmitate one-month formulation
    Navarro Pablo, R.
    Romero Guillena, S. L.
    Gotor Sanchez Luengo, F.
    Plasencia Garcia de Diego, B. O.
    Santamaria Gomez, O.
    EUROPEAN PSYCHIATRY, 2018, 48 : S125 - S126
  • [47] Non-inferiority efficacy trial of risperidone long-acting injection vs. olanzapine tablets
    Rabinowitz, J
    Khan, A
    Augustyns, I
    Ingham, M
    SCHIZOPHRENIA RESEARCH, 2006, 81 : 94 - 95
  • [48] RELAPSE PREVENTION IN SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER WITH RISPERIDONE LONG-ACTING INJECTABLE VERSUS QUETIAPINE: RANDOMIZED, LONG-TERM, OPEN-LABEL, CLINICAL TRIAL RESULTS (CONSTATRE)
    Gaebel, W.
    Bergmans, P.
    de Arce, R.
    Rouillon, F.
    Cordes, J.
    Eriksson, L.
    Schreiner, A.
    Smeraldi, E.
    EUROPEAN PSYCHIATRY, 2009, 24
  • [49] Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial (vol 35, pg 2367, 2010)
    Gaebel, Wolfgang
    Schreiner, Andreas
    Bergmans, Paul
    de Arce, Rosario
    Rouillon, Frederic
    Cordes, Joachim
    Eriksson, Lars
    Smeraldi, Enrico
    NEUROPSYCHOPHARMACOLOGY, 2011, 36 (02) : 548 - 548
  • [50] Long-acting injectable risperidone in treatment refractory patients: A 14-week open-label pilot study
    Procyshyn, Ric M.
    Barr, Alasdair M.
    Flynn, Sean
    Schenk, Chris
    Ganesan, Soma
    Honer, William G.
    SCHIZOPHRENIA RESEARCH, 2010, 123 (2-3) : 273 - 275
12345